ADMA Biologics, Inc. (NASDAQ: ADMA) is excited to announce that the company has received U.S. Food and Drug Administration (“FDA”) approval for its eighth ADMA BioCenters plasma collection facility in Hammond, Louisiana! This facility is now licensed to collect, and introduce into interstate commerce, human source plasma for further manufacturing in the U.S. and has already commenced operations and initiated source plasma collection in the second quarter of 2022. It marks a major milestone for ADMA’s end-to-end commercial biopharmaceutical operations and is set to revolutionize the industry.
ADMA is thrilled to announce that its plasma collection network has successfully expanded with the recent approval from the FDA! This achievement allows ADMA to reach its goal of plasma supply self-sufficiency, and sets the foundation for ongoing revenue growth and profitability. We extend our heartfelt appreciation to the FDA for their expeditious review of the Hammond, LA Biologics License Application (“BLA”), which was granted earlier than expected. The unwavering commitment of the BioCenters team has been instrumental in this victory.
ADMA BioCenters is on track to reach its goal of having ten FDA-approved plasma collection centers, collecting both normal source plasma and Respiratory Syncytial Virus (RSV) hyperimmune plasma, by the end of 2023. With eight FDA-licensed plasma collection centers already in place, the company is steadily advancing towards this milestone. Brian Lenz, Executive Vice President, Chief Financial Officer, and General Manager of ADMA BioCenters, has expressed his enthusiasm for the progress made thus far.
At our new, state-of-the-art plasma collection center, donors can enjoy a streamlined, comfortable, and safe donation experience. Our automated registration process, high-tech collection equipment, free Wi-Fi in the donor area, individual flat-screen TVs with cable at every station, and a staff of 50 highly trained healthcare workers, all work together to ensure an efficient and pleasant donation process. We are proud to use the Haemonetics NexSys Persona® plasma collection system, the gold standard in plasma collection.
About ADMA BioCenters
ADMA BioCenters is an FDA-licensed facility that specializes in the collection of human plasma for the production of life-saving medications. Our experienced team of experts have dedicated decades to the specialized field of plasma collection, ensuring that our donation environments are safe, professional, and pleasant. We abide by all FDA regulations, including cGMP (current good manufacturing practices), so that the medications we produce are the highest quality and most effective.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a revolutionary biopharmaceutical company that is dedicated to the manufacture, marketing, and development of specialty plasma-derived biologics for the treatment and prevention of certain infectious diseases. With three FDA-approved plasma-derived biologics already on the market—BIVIGAM®, ASCENIV™, and NABI-HB®—ADMA is committed to providing enhanced immunity against a range of infectious diseases. Their FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida is the cornerstone of their success, and their subsidiary, ADMA BioCenters, is an FDA-approved source plasma collector in the U.S. In addition, ADMA has been awarded U.S. Patents and European Patent No. 3375789, among others, related to their products and product candidates. Together, they are on a mission to provide targeted treatments and preventative measures to niche patient populations.